Kevin Joseph Fitzgerald sold $120k of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 496 shares at an average of $241.69, traded Feb 28, 2025, filed Mar 3, 2025.
Score components
- +15RoleOfficer
- +10Trade size$120k at market
- 0Share of holdings soldSold 3.9% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | SOpen-market sale Common Stock | -27 | $236.51 | $6,386 | 12,854 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -21 | $238.33 | $5,005 | 12,833 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -22 | $239.18 | $5,262 | 12,811 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -48 | $240.32 | $12k | 12,763 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -79 | $241.51 | $19k | 12,684 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -187 | $242.44 | $45k | 12,497 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -75 | $243.23 | $18k | 12,422 | Mar 3, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stock | -37 | $244.11 | $9,032 | 12,385 | Mar 3, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 35Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $16M 50,937 shares | -63% | |
| 15Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $3.1M 11,250 shares | -40% | |
| 23Weak | ALNYbuy ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $10k 36 shares | - | |
| 45Moderate | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8,383 36 shares | -100% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $2.2M 7,440 shares | -98% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $2.9M 9,766 shares | -40% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $945k 3,877 shares | -4% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $308k 1,264 shares | -3% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $621k 2,557 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.